TickerFacts.

A business in context

CRSP research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-23 · 8022 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-10-19 · 0001193125-26-428010

  2. 4 · Ownership change

    Report date 2026-10-16 · 0001193125-26-426878

  3. 8-K · Current report

    Report date 2026-10-19 · 0001193125-26-425243 · Items 5.02,9.01

  4. 4 · Ownership change

    Report date 2026-10-14 · 0001193125-26-424317

  5. 4 · Ownership change

    Report date 2026-10-13 · 0001193125-26-423057

  6. 4 · Ownership change

    Report date 2026-10-13 · 0001193125-26-423056

  7. 4 · Ownership change

    Report date 2026-10-06 · 0001193125-26-418101

  8. 4 · Ownership change

    Report date 2026-09-22 · 0001193125-26-401237

  9. 4 · Ownership change

    Report date 2026-09-17 · 0001193125-26-396944

  10. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-330672

  11. 8-K · Current report

    Report date 2026-08-03 · 0001193125-26-330644 · Items 2.02,9.01

  12. 8-K · Current report

    Report date 2026-06-04 · 0001193125-26-257593 · Items 5.02,5.03,5.07,9.01

  13. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-204188

  14. 8-K · Current report

    Report date 2026-05-04 · 0001193125-26-204147 · Items 2.02,9.01

  15. DEF 14A · Proxy statement

    Report date 2026-06-04 · 0001193125-26-165158

  16. 8-K · Current report

    Report date 2026-03-16 · 0001193125-26-108333 · Items 1.01,2.03,3.02,9.01

  17. 8-K · Current report

    Report date 2026-03-10 · 0001193125-26-101073 · Items 8.01,9.01

  18. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-048957

  19. 8-K · Current report

    Report date 2026-02-12 · 0001193125-26-048873 · Items 2.02,9.01

  20. 8-K · Current report

    Report date 2026-01-12 · 0001193125-26-009880 · Items 8.01

  21. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-273337

  22. 8-K · Current report

    Report date 2025-11-10 · 0001193125-25-273329 · Items 2.02,9.01

  23. 8-K · Current report

    Report date 2025-10-15 · 0001193125-25-240282 · Items 8.01,9.01

  24. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-102052

  25. 8-K · Current report

    Report date 2025-08-04 · 0000950170-25-102027 · Items 2.02,9.01

  26. 8-K · Current report

    Report date 2025-06-26 · 0000950170-25-090170 · Items 8.01

  27. 8-K · Current report

    Report date 2025-06-05 · 0000950170-25-083799 · Items 5.03,5.07,9.01

  28. 8-K · Current report

    Report date 2025-05-19 · 0000950170-25-074428 · Items 1.01,8.01,9.01

  29. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-064468

  30. 8-K · Current report

    Report date 2025-05-06 · 0000950170-25-064435 · Items 2.02,9.01

  31. DEF 14A · Proxy statement

    Report date 2025-06-05 · 0000950170-25-054711

  32. 8-K · Current report

    Report date 2025-03-24 · 0000950170-25-045232 · Items 5.02,9.01

  33. 10-K · Annual report

    Report date 2024-12-31 · 0000950170-25-017899

  34. 8-K · Current report

    Report date 2025-02-11 · 0000950170-25-017879 · Items 2.02,9.01

  35. SC 13G/A · Ownership disclosure

    0001104659-24-127131

  36. 10-Q · Quarterly report

    Report date 2024-09-30 · 0000950170-24-121105

  37. 8-K · Current report

    Report date 2024-11-05 · 0000950170-24-121103 · Items 2.02,9.01

  38. 10-Q · Quarterly report

    Report date 2024-06-30 · 0000950170-24-090746

  39. 8-K · Current report

    Report date 2024-08-05 · 0000950170-24-090727 · Items 2.02,9.01

  40. 8-K · Current report

    Report date 2024-05-30 · 0000950170-24-067660 · Items 5.02,5.03,5.07,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-23 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 2 transaction rows2SGrant / award: 0 transaction rows0AExercise / conversion: 4 transaction rows4MTax / exercise payment: 0 transaction rows0FGift: 1 transaction rows1G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

9 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-09-22
2026-09-24
KASINGER JAMES R.S · Sale
Disposed
Common Shares10400.060.24
2026-09-22
2026-09-24
KASINGER JAMES R.M · Exercise / conversion
Acquired
Common Shares10400.013.62
2026-09-22
2026-09-24
KASINGER JAMES R.M · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
10400.00.0
2026-09-17
2026-09-21
Behbahani AliS · Sale
Disposed
Common Shares13679.057.09
2026-09-17
2026-09-21
Behbahani AliM · Exercise / conversion
Acquired
Common Shares30000.014.0
2026-09-17
2026-09-21
Behbahani AliM · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
30000.00.0
2026-08-07
2026-08-11
Prasad RajuG · Gift
Disposed
Common Shares750.00.0
2025-08-06
2026-09-21
Behbahani AliJ · Other (see filing)
Acquired
Common Shares60.00.0
2025-08-06
2026-09-21
Behbahani AliJ · Other (see filing)
Acquired
Common Shares15.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-23 · 1658 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001674416CRISPR Therapeutics AG

No parent relationship is available in this import; this is not proof of independence.

Legal Entity Identifier
506700O6IRRIQLT3W370
GLEIF legal name
CRISPR Therapeutics AG
Entity / LEI registration status
ACTIVE / ISSUED
Reference data updated
2026-01-09T14:20:20Z

direct-parent: no parent LEI supplied

ultimate-parent: no parent LEI supplied

GLEIF legal entity reference data · retrieved 2026-10-23 · 1197 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • CRISPR Therapeutics · alias · wikidata
  • CRISPR Therapeutics AG · former SEC name · 2016-05-13 to 2026-10-21
Explore headquarters map ↗

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$37.31M$40.08M
2023-12-31$371.21M$410.45M
2022-12-31$1.20M$1.38M
2021-12-31$914.96M$1.14B
2020-12-31$719.0K$936.0K
2019-12-31$289.59M$381.64M
2018-12-31$3.12M$4.19M
2017-12-31$41.00M$56.35M

Bureau of Labor Statistics · retrieved 2026-10-23 · 9 selected series; gaps remain missing

Explore the CPI history ↗